10x Genomics, Inc.
MX ˙ BMV ˙ US88025U1097
SecurityMX:TXG / 10x Genomics, Inc.
InstitutionStrs Ohio
Latest Disclosed Ownership48,100 shares
Latest Disclosed Value $ 1,021,163
Strs Ohio reports 8.56% decrease in ownership of TXG / 10x Genomics, Inc.

On April 24, 2026 - Strs Ohio filed a 13F-HR form disclosing ownership of 48,100 shares of 10x Genomics, Inc. (MX:TXG) valued at $1,021,163 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 52,600 shares of 10x Genomics, Inc.. This represents a change in shares of -8.56% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F 10X GENOMICS COM_STK 88025U109 48,100 -4,500 -8.56 1,021 19.14 0.0041
2026-02-02 2025-12-31 13F 10X GENOMICS COM_STK 88025U109 52,600 -6,500 -11.00 858 24.20 0.0032
2025-10-30 2025-09-30 13F 10X GENOMICS INC- COM_STK 88025U109 59,100 -3,500 -5.59 691 -4.70 0.0025
2025-08-04 2025-06-30 13F 10X GENOMICS INC- COM_STK 88025U109 62,600 62,600 725 0.0027
2024-01-30 2023-12-31 13F 10X GENOMICS INC- COM 88025U109 0 -13,789 -100.00 0 0.0000
2023-10-26 2023-09-30 13F/A-1 10X GENOMICS INC- COM 88025U109 13,789 1,986 16.83 1 0.0025
2023-10-26 2023-09-30 13F 10X GENOMICS INC- COM 88025U109 13,789 1,986 1 0.0025
2023-07-31 2023-06-30 13F 10X GENOMICS INC- COM 88025U109 11,803 11,803 1 0.0028
2022-07-25 2022-06-30 13F 10X GENOMICS INC- COM 88025U109 0 -719 -100.00 0 -100.00
2022-04-21 2022-03-31 13F 10X GENOMICS INC- COM 88025U109 719 0 0.00 54 -49.53 0.0002
2022-01-24 2021-12-31 13F 10X GENOMICS INC- COM 88025U109 719 0 0.00 107 2.88 0.0004
2021-10-22 2021-09-30 13F 10X GENOMICS INC- COM 88025U109 719 0 0.00 104 -25.71 0.0004
2021-07-26 2021-06-30 13F 10X GENOMICS INC- COM 88025U109 719 -6,172 -89.57 140 -88.77 0.0005
2021-04-23 2021-03-31 13F 10X GENOMICS INC- COM 88025U109 6,891 255 3.84 1,247 32.80 0.0047
2021-01-25 2020-12-31 13F 10X GENOMICS INC- COM 88025U109 6,636 316 5.00 939 19.31 0.0036
2020-12-14 2020-09-30 13F 10X GENOMICS INC- COM 88025U109 6,320 6,320 787 0.0033
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.